PARP inhibitors may be effective against non-small-cell lung cancer: Study
Yesterday 03:49 下午 ET • BMRN
A new study published in Oncogene reportedly suggests PARP inhibitors such as BioMarin's (BMRN +0.7%) BMN 673 and Tesaro's (TSRO...查看全文
医药邦at壹专家2013-08-14 16:10
$拜玛林制药(BMRN)
$PARP inhibitors may be effective against non-small-cell lung cancer: Study
A new study published in Oncogene reportedly suggests PARP inhibitors such as BioMarin's (BMRN +0.7%) BMN 673 and Tesaro's (TSRO +0.1%) Niraparib may be effective in ...查看全文
12月31日,拜玛林制药(BMRN.US)公布财报,公告显示公司2023财年净利润为1.68亿美元,同比增加18.31%;其中营业收入为24.19亿美元,同比增加18.17%,每股基本收益为0.89美元。 从资产负债表来看,拜玛林制药... 网页链接
智通财经APP获悉,美银全球股票团队表示,预计今年晚些时候美股大盘将低于当前水平,但科技股仍存在大量投资机会。策略师安东尼·卡萨马西诺(Anthony Cassmassino)编制了一份研究团队给出的行业首选名单。以下是美银对美股医疗保健领域... 网页链接
纳斯达克100指数的成分股中,基因组鉴定公司Illumina收涨将近17.0%领跑,阿根廷电商Mercadolibre涨超10.7%,京东ADR涨约10.3%,Lucid涨约9.0%,Peloton涨约6.4%,拜玛林制药(BMRN)涨超5.4%,拼多多ADR涨超5.3%,T-Mobile、爱彼迎(ABNB... 网页链接
成分股拜玛林制药(BMRN)收涨超10.3%领跑,该公司用于改善5岁及以上年龄段软骨发育不全儿童成长、打开骨骺的药品Voxzogo获得美国食品药品管理局(FDA)加速批准。财捷(INTU)涨约10.1%,在标普500指数的成分股中领涨,该公司业绩发布后... 网页链接
智通财经APP预告,2021年4月30日,港美股上市公司活动及香港重要财经会议信息情况如下: 00:00 Altabancorp(ALTA.US) Altabancorp(ALTA.US)2021年第一季度业绩电话会 网络转播 01:00 凯撒铝业(KALU.US) 凯撒铝业(KALU.US)2021年第一季度... 网页链接
$拜玛林制药(BMRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001048477-24-000079 Size: 15 KB 网页链接
$拜玛林制药(BMRN)$ 144 Report of proposed sale of securities Accession Number: 0001959173-24-003411 Act: 33 Size: 7 KB 网页链接
$拜玛林制药(BMRN)$ 144 Report of proposed sale of securities Accession Number: 0001959173-24-003371 Act: 33 Size: 7 KB 网页链接
$拜玛林制药(BMRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001048477-24-000077 Size: 6 KB 网页链接
$拜玛林制药(BMRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001048477-24-000075 Size: 10 KB 网页链接
$拜玛林制药(BMRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001048477-24-000073 Size: 6 KB 网页链接
$拜玛林制药(BMRN)$ 144 Report of proposed sale of securities Accession Number: 0001959173-24-003199 Act: 33 Size: 4 KB 网页链接
$拜玛林制药(BMRN)$ 144 Report of proposed sale of securities Accession Number: 0001959173-24-003149 Act: 33 Size: 4 KB 网页链接
$拜玛林制药(BMRN)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001048477-24-000070 Act: 34 Size: 6 MB 网页链接
$拜玛林制药(BMRN)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001048477-24-000066 Act: 34 Size: 426 KB 网页链接